Sionna Therapeutics (SION) Accounts Payables (2024 - 2026)

Sionna Therapeutics has disclosed Accounts Payables across 3 years of filings, most recently posting $2.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.1 million, down 57.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 57.98% YoY), and the FY2025 annual result was $769000.0, down 35.16% from the prior year.
• Accounts Payables came in at $2.1 million for Q1 2026 at Sionna Therapeutics, up from $769000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.0 million in Q1 2025 to a low of $769000.0 in Q4 2025.
• The 3-year median for Accounts Payables is $1.3 million (2024), against an average of $1.9 million.
• Across the five-year window, Accounts Payables sank 35.16% in 2025 and sank 57.98% in 2026, its largest moves.
• Sionna Therapeutics' Accounts Payables stood at $1.2 million in 2024, then slumped by 35.16% to $769000.0 in 2025, then soared by 174.25% to $2.1 million in 2026.
• The last three Accounts Payables figures came in at $2.1 million (Q1 2026), $769000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.